Enhanced Survival in Advanced Breast Cancer with New PIK3CA-Targeted Treatment Combination
A groundbreaking phase 3 trial reveals that combining inavolisib with palbociclib and fulvestrant significantly prolongs survival in patients with PIK3CA-mutated advanced breast cancer, offering new hope through precision medicine.
Recent clinical research has demonstrated promising advancements in the treatment of advanced breast cancer characterized by PIK3CA mutations, which are present in approximately 35-40% of hormone receptor–positive cases. A significant phase 3 trial, led by researchers at Mass General Brigham, evaluated the effectiveness of a three-drug regimen combining inavolisib, palbociclib, and fulvestrant. The study revealed that patients receiving this combination experienced increased overall survival times, with a median of 34 months compared to 27 months in the control group. Additionally, these patients showed longer periods without disease progression (17.2 months vs. 7.3 months) and higher tumor reduction rates (62.7% vs. 28.0%). The treatment regimen received FDA approval last October based on favorable progression-free survival data, emphasizing its potential as a new standard for this subset of breast cancer patients.
Despite its benefits, the combination was associated with some notable side effects, including elevated blood sugar levels, mouth sores, diarrhea, and eye issues. Serious adverse events occurred in 27.3% of patients, leading to discontinuation in 6.8%, highlighting the importance of monitoring and managing side effects. The research team plans further studies to assess safety and efficacy in underrepresented groups, such as older adults over 65.
These findings underscore the importance of PIK3CA mutation testing in advanced breast cancer and support the integration of precision oncology approaches to improve patient outcomes. The study's results were published in the "New England Journal of Medicine" and presented at the ASCO annual meeting. The promising effects of this combination mark a significant step forward in targeted breast cancer therapies, offering hope for enhanced survival rates in this patient population.
Source: https://medicalxpress.com/news/2025-06-drug-combination-survival-patients-pik3ca.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Tennessee Lowers the Standards for Ballad Health's Hospital Monopoly Amidst Concerns
Tennessee has lowered the standards for Ballad Health's hospital monopoly, allowing continued operation despite poor performance scores and limiting public access to performance data. The change raises concerns about transparency and healthcare quality.
Genetic Variant Associated with Increased Risk of Long COVID Symptoms
A new study uncovers a genetic variant near FOXP4 linked to a 60% increased risk of developing long COVID, highlighting the role of lung function in post-COVID symptoms.
US Experiences Its Worst Measles Outbreak of the 21st Century in 2025
The US faces its worst measles outbreak of the 21st century in 2025, with over 1,200 cases and multiple deaths, driven by declining vaccination rates and misinformation. Learn more about this alarming resurgence.